ClinicalTrials.gg
CompletedNCT05875493Updated Apr 4, 2025

A Food Effect Study of JAB-21822 in Healthy Subjects

A Phase 1 interventional study of JAB-21822 and JAB-21822 in Food Effect in Healthy Participants, sponsored by Allist Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of JAB-21822 following single dose administration with and without a meal

Read the detailed description

This is an open-label,randomized, 2-cycle,2-period crossover,food effect study. On Day 1 of each period, subjects will receive a single oral dose of JAB-21822 administered either under fasting conditions or following a standardized high-fat/high-calorie meal. PK sampling for JAB-21822 will be collected predose and postdose. There will be a washout period between doses.

02

Conditions studied

  • Food Effect in Healthy Participants
03

In context

Lead sponsor

Allist Pharmaceuticals, Inc. is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female , between 18 and 45 years of age
  • Bodyweight (male) ≥50kg, Bodyweight (Female) ≥45kg; within the range of 19 to 25 kg/m2, inclusive
  • No abnormalities identified in the judgement of investigator at screening
  • Written prior to any study specific procedures

Exclusion criteria

Exclusion Criteria:

  • History of disease or disorder
  • History of interstitial pneumonia, pulmonary fibrosis, and other interstitial lung diseases
  • History of dysphagia or any gastrointestinal disease that would potentially alter absorption of drug
  • COVID-19 positive at screening or baseline
  • Allergic to JAB-21822 and any of the tablet's ingredients, history of or allergy to drug or food
  • Received surgical procedure within 3 months at screening
  • Blood donation within the 3 months or planing to donate during the study
  • Participated in another clinical trial of biological agents within 6 months at screening, or any other clinical trial within 3 months at screening
  • History of drug abuse or positive urine drug test
  • Received the vaccine within 3 months at screening or planning to receive during the study
  • Overtake of achole,tea and coffee prior to first dosing and unable to control during the study
  • Special dietary requirements or unable to control during the study
  • , , , and syphilis positive
  • Pregnant or breast-feeding women or positive of blood pregnancy test
  • Subjects who are considered to be unacceptable in this study under the opinion of the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    A-JAB-21822

    Dosing in the fasted state followed by fed dosing

    Drug: JAB-21822

  • Experimental
    B-JAB-21822

    Dosing in the fed state followed by fasted dosing

    Drug: JAB-21822

Interventions

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration (AUC) 0 to∞

    Area under the plasma concentration time curve of JAB-21822

    Time frame: 31days

  2. Area under plasma concentration (AUC) 0 to t

    Area under the plasma concentration time curve of JAB-21822

    Time frame: 31days

  3. Plasma concentration ( Cmax)

    Highest observed plasma concentration of JAB-21822

    Time frame: 31days

Secondary outcomes

  1. Time to achieve Cmax (Tmax)

    Time of highest observed plasma concentration of JAB-21822

    Time frame: 31days

  2. Elimination rate constant (λz)

    Elimination rate constant based on the terminal phase of unchanged form of JAB-21822

    Time frame: 31days

  3. Concentration half-life (T1/2)

    Elimination half-life of unchanged form of JAB-21822

    Time frame: 31days

  4. Absorption lag-time (Tlag)

    Elimination lag-time of JAB-21822

    Time frame: 31days

  5. Apparent volume of distribution (Vz/F)

    Apparent volume of distribution based on the terminal phase of unchanged form of JAB-21822

    Time frame: 31days

  6. Apparent clearance (CL/F)

    Apparent total body clearance of unchanged form of JAB-21822

    Time frame: 31days

  7. Number of participants with adverse events (AEs) and serious adverse events(SAEs)

    Incidence,duration and severity of adverse events and serious adverse events according to NCI-CTCAE v5.0

    Time frame: 31days

  8. Number of subjects with abnormal lab parameters

    Abnormal values of lab parameters

    Time frame: 31days

  9. Number of subjects with abnormal electrocardiogram (12-lead ECG)

    Prolongation of the QTc interval

    Time frame: 31days

  10. Number of subjects with abnormal systolic and diastolic blood pressure

    Abnormal values in systolic and diastolic blood pressure

    Time frame: 31days

  11. Number of subjects with abnormal pulse rate

    Abnormal values in pulse rate

    Time frame: 31days

  12. Number of subjects with abnormal respiratory rate

    Abnormal values in respiratory rate

    Time frame: 31days

  13. Number of subjects with abnormal body temperature

    Abnormal values of body temperature

    Time frame: 31days

07

Study locations

1 site
  • Beijing GoBroad Boren Hospital
    Beijing, Beijing 100070, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jun 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2023
First posted
May 25, 2023
StartActual
May 12, 2023
Primary completionActual
Jun 14, 2023
CompletionActual
Jun 14, 2023
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05875493
Responsible party
Sponsor
First posted
May 25, 2023
Start date
May 12, 2023
Primary completion
Jun 14, 2023
Completion
Jun 14, 2023
Last update
Apr 4, 2025

Study contacts

He Qing B.Pharm
principal investigator · Beijing Gaobo Boren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glecirasib

Start the discussion